Avanos Medical (FRA:8HH) Research & Development: €19.8 Mil (TTM As of Mar. 2026)


FRA:8HH Avanos Medical Inc FRA:8HH
62 GF Score
Price €21.40
GF Value €16.66
! 5 Warning Signs
View Full Analysis

What is Avanos Medical Research & Development?

Avanos Medical FRA:8HH 62 Research & Development is €19.8 Mil as of Mar. 2026. GuruFocus rates FRA:8HH with a GF Score™ of 62/100 and a GF Value™ of €16.66. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Avanos Medical's Research & Development for the three months ended in Mar. 2026 was €4.5 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €19.8 Mil.

Avanos Medical  (FRA:8HH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Avanos Medical Research & Development Related Terms

Avanos Medical Research & Development Historical Data

* Premium members only.

The historical data trend for Avanos Medical's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avanos Medical Research & Development Chart

Avanos Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.08 27.57 24.94 25.02 19.90

Avanos Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.03 5.11 5.21 4.50
FRA:8HH
62GF Score
Avanos Medical Inc FRA:8HH
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avanos Medical Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €19.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €19.8 Mil mean?
Avanos Medical (FRA:8HH) has a Research & Development of €19.8 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Avanos Medical and its competitors.
Is Avanos Medical's Research & Development too high?
Avanos Medical's current Research & Development is €19.8 Mil. Overall, Avanos Medical has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Avanos Medical's Research & Development compare to LMRI and AORT?
Avanos Medical's Research & Development of €19.8 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Avanos Medical and its competitors. Avanos Medical's current Research & Development is €19.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avanos Medical stock overvalued right now?
Avanos Medical (FRA:8HH) has a current Research & Development of €19.8 Mil. The stock's GF Value™ is €16.66, compared to a current price of €21.40 — trading 28.5% above its estimated fair value. The current Research & Development is €19.8 Mil. Avanos Medical's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Avanos Medical (FRA:8HH), the current Research & Development is €19.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Avanos Medical (FRA:8HH) Overvalued in 2026?

Based on GuruFocus' analysis, Avanos Medical stock appears to be overvalued. The current stock price of €21.40 is trading 28.5% above its estimated GF Value™ of €16.66.

Key valuation signals for FRA:8HH:

  • Research & Development: €19.8 Mil
  • GF Value™: €16.66 vs. price of €21.40 (28.5% above fair value)
  • GF Score™: 62/100 with 5 warning signs

No single metric tells the full story. See the FRA:8HH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Avanos Medical Business Description

Other Exchanges AVNS:USA
Address 5405 Windward Parkway, Suite 100 South, Alpharetta, GA, USA, 30004
Avanos Medical Inc is a medical technology company engaged in the development and commercialization of products for pain management and patient care. The company has two reportable segments: Specialty Nutrition Systems and Pain Management and Recovery. The Specialty Nutrition Systems segment provides enteral feeding and neonatal products. The Pain Management and Recovery segment offers surgical pain and recovery products, including pain pumps and radiofrequency ablation solutions for the treatment of chronic pain.
62GF Score

Get the complete analysis for FRA:8HH

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.40
Price
€16.66
GF Value